Suppr超能文献

阿育吠陀64号,一种用于治疗流感样疾病的阿育吠陀复方制剂——一项初步研究的结果

AYUSH 64, a polyherbal Ayurvedic formulation in Influenza-like illness - Results of a pilot study.

作者信息

Gundeti Manohar S, Bhurke Laxman W, Mundada Pallavi S, Murudkar Sanjay, Surve Ashita, Sharma Ramavatar, Mata Sunita, Rana Rakesh, Singhal Richa, Vyas Neera, Khanduri Shruti, Sharma B S, Srikanth N, Dhiman K S

机构信息

Research Officer (Ayu) Incharge, RRAP Central Ayurveda Research Institute for Cancer (CCRAS), Mumbai, India.

Research Officer (Ayu), RRAP Central Ayurveda Research Institute for Cancer (CCRAS), Mumbai, India.

出版信息

J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100325. doi: 10.1016/j.jaim.2020.05.010. Epub 2020 May 14.

Abstract

BACKGROUND

Influenza-like Illness (ILI) refers to a wide range of viral infections with an important cause of morbidity and mortality worldwide. The global incidence of ILI is estimated at 5-10% in adults and 20-30% in children. In India influenza accounts for 20-42% of monthly acute medical illness hospitalizations during the peak rainy season. AYUSH-64, a poly-herbal drug, is in practice for 40 years for various clinical conditions like fevers, microfilaremia, and inflammatory conditions.

OBJECTIVE

A pilot study was conducted to evaluate the safety and efficacy of Ayurvedic formulation, AYUSH-64 in clinically diagnosed ILI for accelerating the recovery.

MATERIAL AND METHODS

A prospective, open-label, nonrandomized, single group, single-center pilot clinical study with pre-test and post-test design was conducted at Raja Ramdeo Anandilal Podar Central Ayurveda Research Institute for Cancer, Mumbai, an institute of Central Council for Research in Ayurvedic Sciences (CCRAS) between June 2018 and July 2019. A total of 38 participants of clinically diagnosed ILI (18-65 years) were studied with an one-week intervention of 'AYUSH 64' in a dose of 3 gm/day and three weeks post-treatment observation period. Assessment of parameters viz. improvement in the symptoms of ILI, frequency of usage of acetaminophen, antihistaminic and cough syrup, hematology, liver function and kidney function tests along with incidence of secondary complications, and time to return to a normal routine was done.

RESULTS

One-week intervention of AYUSH 64 helped to recover from ILI symptoms with reduced frequency of usage of acetaminophen and antihistaminic. The intervention was safe on hematology and biochemical parameters. No serious adverse effects were observed during the study.

CONCLUSION

AYUSH 64 along-with standard care in ILI is safe and efficacious and this may be used in other viral infections with pyrexia as add-on to standard care for early recovery and better outcome.

摘要

背景

流感样疾病(ILI)指多种病毒感染,是全球发病和死亡的一个重要原因。据估计,ILI在成人中的全球发病率为5%-10%,在儿童中为20%-30%。在印度,在雨季高峰期,流感占每月急性内科疾病住院病例的20%-42%。阿育吠陀复方药物AYUSH-64已在临床应用40年,用于治疗各种临床病症,如发热、微丝蚴血症和炎症性病症。

目的

开展一项试点研究,以评估阿育吠陀制剂AYUSH-64在临床诊断的ILI中加速康复的安全性和有效性。

材料与方法

于2018年6月至2019年7月在孟买的拉贾·拉姆迪奥·阿南迪拉尔·波达尔中央阿育吠陀癌症研究所进行了一项前瞻性、开放标签、非随机、单组、单中心试点临床研究,采用前后测试设计。该研究所隶属于阿育吠陀科学中央研究理事会(CCRAS)。共有38名临床诊断为ILI的参与者(年龄在18-65岁之间)接受研究,给予为期一周的“AYUSH 64”干预,剂量为3克/天,并进行为期三周的治疗后观察期。评估了以下参数:ILI症状的改善情况、对乙酰氨基酚、抗组胺药和止咳糖浆的使用频率、血液学、肝功能和肾功能检查,以及继发性并发症的发生率和恢复正常日常生活的时间。

结果

AYUSH-64为期一周的干预有助于ILI症状的恢复,同时降低了对乙酰氨基酚和抗组胺药的使用频率。该干预对血液学和生化参数是安全的。研究期间未观察到严重不良反应。

结论

AYUSH-64联合ILI的标准治疗是安全有效的,可用于其他伴有发热的病毒感染,作为标准治疗的附加治疗,以实现早期康复和更好的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7ee/8718941/474b7bbe1623/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验